Document:

Exhibit 10.2

 

CONSULTING
AGREEMENT

 

This
Consulting Agreement (this “Agreement”) is entered into as of December 29, 2017 (the “Effective Date”),
by and between DanDrit Biotech USA, Inc., a Delaware corporation (the “Company”) and RS Group ApS, a Danish
limited company, organized under the Danish Act on Limited Companies of the Kingdom of Denmark (“RS Group”).

 

WHEREAS,
commencing on October 1, 2017, RS Group has provided and will continue to provide services on behalf of the Company and its wholly
owned subsidiary (the “Services”); and

 

WHEREAS,
the Company desires to compensate RS Group for the Services and to continue to engage RS Group to perform the Services on behalf
of the Company during the Term (as defined below), and RS Group desires to be engaged to perform such Services, on the terms and
conditions set forth herein.

 

NOW,
THEREFORE, in consideration of the mutual promises, covenants and agreements contained herein, and intending to be legally
bound hereby, the Company and RS Group do hereby agree as follows:

 

1.  Recitals.
The foregoing recitals are true and correct and are incorporated herein as if repeated at length.

 

2.  Services.
RS Group hereby agrees to provide the Services to the Company and such other services which are mutually agreeable by both parties
on an ad hoc basis during the Term set forth in Section 3 hereto in consideration for aggregate payments equal to DKK 920,000,
and $221,169 (total value of $367,221.60) which shall be deemed fully earned and payable by the Company to RS Group as of the
Effective Date.

 

3.  Expenses.
RS Group agrees to pay for all of its own expenses, including, without limitation, all expenses relating to telephone conferences,
mailing and labor, other than expenses related to extraordinary items including travel, entertainment and other activities required
by or specifically requested by the Company.

 

4.  Term.
The term of this Agreement will continue through March 31, 2018 (the “Term”) unless otherwise modified in writing
by the parties pursuant to Section 5 hereto.

 

5.  Amendments;
Entire Agreement. This Agreement may not be amended, modified or terminated except by a writing executed by the parties
hereto. This Agreement contains the entire understanding of the parties hereto and no agreements or representations, oral or otherwise,
express or implied, with respect to the subject matter hereof have been made by either party, which are not set forth expressly
in this Agreement. This Agreement supersedes all negotiations, preliminary agreements, and all prior and contemporaneous discussions
and understandings of the parties hereto and/or their affiliates.

 

    

     

    

 

6.  Counterparts.
This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together
will constitute one and the same instrument.

 

7.  Notices.
All notices and other communications required or permitted by this Agreement to be delivered by the Company or RS Group to
the other party shall be delivered in writing, either personally or by registered, certified or express mail, return receipt requested,
postage prepaid, respectively, to the headquarters of the Company, or to the address of record of RS Group on file at the Company.

 

8.  Successors
and Assigns. This Agreement shall not be assignable by RS Group without prior written consent of the Company. The Company
may assign its rights hereunder to: (a) any corporation resulting from any merger, consolidation or other reorganization to which
the Company is a party, or (b) any corporation, partnership, association or other person to which the Company may transfer all
or substantially all of the assets and business of the Company existing at such time.

 

9.  Severability:
Provisions Subject to Applicable Law. All provisions of this Agreement shall be applicable only to the extent that they
do not violate any applicable law, and are intended to be limited to the extent necessary so that they will not render this Agreement
invalid, illegal or unenforceable under any applicable law. If any provision of this Agreement or any application thereof shall
be held to be invalid, illegal or unenforceable, then such provision shall be enforced to the maximum extent permissible and lawful
so as to effect the intent of this Agreement, and the validity, legality and enforceability of the other provisions of this Agreement
or of any other application of such provision shall in no way be affected thereby.

 

10.    Definitions,
Headings, and Number. A term defined in any part of this Agreement shall have the defined meaning wherever such term is
used herein. The headings contained in this Agreement are for reference purposes only and shall not affect in any manner the meaning
or interpretation of this Agreement.

 

11.    Governing
Law. This Agreement and the parties’ performance hereunder shall be governed by and interpreted under the laws of the
state of Delaware without reference to conflict of law principals thereof.

 

12.    Construction
and Interpretation. This Agreement has been discussed and negotiated by, all parties hereto and their counsel and shall
be given a fair and reasonable interpretation in accordance with the terms hereof, without consideration or weight being given
to it having been drafted by any party hereto or its counsel.

 

    	 	2	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date.

 

	DANDRIT BIOTECH USA, INC.	 	RS GROUP APS
	 	 	 	 	 
	By: 	/s/
    Robert Wolfe	 	By:	/s/
    Henrik Grønfeldt-Sørensen
	Name:	Robert
    Wolfe	 	Name:	Henrik
    Grønfeldt-Sørensen
	Title:	Chief
    Financial Officer	 	Title:	Chief
    Executive Officer

 

 

 

 

Signature
Page to the Consulting Agreement

 

 

3Exhibit 10.4

 

AMENDMENT
NO. 1

TO

CFO
SERVICE AGREEMENT

 

THIS
AMENDMENT NO. 1 (this “Amendment”) to the CFO Service Agreement dated June 30, 2017 (the “Agreement”)
is entered into as of December 29, 2017 (the “Effective Date”), by and among DANDRIT BIOTECH BIOTECH A/S.,
CVR no. 26 02 73 22, a Denmark corporation (the “Company”) and the Crossfield, Inc., Robert E. Wolfe (the “Consultant”
and together with the Company, the “Parties”). Capitalized terms not Defined herein shall have the meaning
set forth in the Agreement.

 

RECITALS:

 

WHEREAS,
on June 30, 2017 the Company and the Consultant entered into the Agreement pursuant to which the Consultant would act as chief
financial officer of the Company and its Parent Company; and

 

WHEREAS,
the Parties now desire to amend the Agreement in order to amend the remuneration, and other provisions, on the terms and conditions
set forth herein.

 

NOW
THEREFORE, on the stated premises and for and in consideration of the mutual covenants and agreements hereinafter set forth
and the mutual benefits to the parties to be derived herefrom, and intending to be legally bound hereby, it is hereby agreed as
follows:

 

1. Recitals.
The foregoing Recitals are true and correct and are incorporated herein by this reference.

 

2. Amendment
to Section 2. Section 2 of the Agreement is hereby amended to read in its entirety:

 

2.1 The
CFO is to be paid USD $240,000 per year. The salary is to be paid monthly in arrears on the last business day of the month, the
first time being on January 31, 2018.

 

2.2 The
payment is made by transfer to a personal or corporate account as decided by the CFO. The tax implications for the CFO resulting
from the above are of no concern to the Company.

 

2.3 The
remuneration is to be discussed with the CEO once a year in December, for the first time in December 2018. Any changes are to
take effect as from January of the following year.

 

2.4 The
parties acknowledge, that the situation in the company can change, such that the CFO responsibilities will require more time and
effort than indicated in this contract. In such a situation the parties will discuss increased time/responsibilities and remuneration.

 

2.5 As
a one-time signing fee the CFO receives at the time of signing this

agreement USD $7,500.00

 

2.6 The
Company will provide full health care benefits to the Consultant until the Agreement is terminated.

 

3. Counterparts.
This Amendment may be executed in counterparts (including by means of facsimile or digital transmission), each of which shall
be deemed an original but all of which, when taken together, will constitute one and the same agreement.

 

IN
WITNESS WHEREOF, the corporate parties hereto have caused this Amendment No. 1 to CFO Service Agreement to be executed by
their respective officers, hereunto duly authorized, as of the Effective Date.

 

	 
	DANDRIT BIOTECH USA, INC.
	 	 	 
	 	By:	 /s/
    Eric Leire
	 	Name:  	Eric
    Leire
	 	Title:
    	CEO

 

	 	CONSULTANT:
	 	 	 
	 	By:	/s/
    Robert Wolfe
	 	Consultant:
    	Crossfield
    Inc.  
	 	Name:  	Robert
    Wolfe
	 	Title:  	Chairman
    & CEO
	 	Date:
    	December
    29, 2017Exhibit  10.5

 

AMENDMENT
NO. 1

TO

CONVERTIBLE
PROMISSORY NOTE

 

This
Amendment No. 1 to Convertible Promissory Note (this “Amendment”), dated as of _________, 2017 (the “Effective
Date”), is entered into by and between DanDrit Biotech USA, Inc., a Delaware corporation (the “Company”),
and ___________ (the “Holder”).

 

RECITALS

 

WHEREAS,
the Company issued to the Holder that certain Convertible Promissory Note in the principal amount of $__________, dated ______________
(the “Original Note”);

 

WHEREAS,
Section 7of the Original Note provides that the Original Note and any provision therein may be amended by the written consent
of the Company and the Holder; and

 

WHEREAS,
the Company and the Holder desire to amend the Original Note.

 

NOW
THEREFORE, in consideration of the mutual promises contained in this Amendment and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Holder, intending to be legally bound, hereby
agree as follows:

 

AGREEMENT

 

		1.	Capitalized
                                         Terms. Except as may be expressly provided herein, all capitalized terms used herein
                                         shall have the meanings assigned to them in the Original Note.

 

		2.	Amendment
                                         to Section 2(b). The parties desire to change the Conversion Price set forth in the
                                         Original Note, and as such, Section 2(b) of the Original Note is hereby amended
                                         and shall read in its entirety as follows:

 

(a)
The conversion price (the “Conversion Price”) shall equal $1.60 per share of Common Stock. 

 

		3.	Conforming
                                         Changes. All provisions in the Original Note and any amendments, attachments, schedules
                                         or exhibits thereto in conflict with this Amendment shall be and hereby are changed to
                                         conform to this Amendment.

 

		4.	Full
                                         Force and Effect. The Original Note is not amended hereby and shall remain in full
                                         force and effect, except as otherwise set forth in this Amendment. The parties hereby
                                         ratify and confirm the terms and conditions of the Original Note, as supplemented and
                                         amended by this Amendment.

 

		5.	Recitals.
                                         The Recitals above are true and correct and are hereby incorporated by reference.

 

		6.	Applicable
                                         law. The substantive laws of the applicable state, as well as terms regarding forum
                                         and jurisdiction, as originally provided in the Original Note shall govern the construction
                                         of this Agreement and the rights and remedies of the parties hereto.

 

		7.	Counterparts.
                                         This Amendment may be executed in counterparts (including by means of facsimile or electronic
                                         transmission), each of which shall be deemed an original but all of which, when taken
                                         together, will constitute one and the same agreement.

 

**
Signature Page Follows **

 

     

     

    

 

IN
WITNESS WHEREOF, the Company and the Holder have made and executed this Amendment effective as of the Effective Date.

  

	COMPANY:

	 	HOLDER:
	 	 	 	 	 
	DANDRIT BIOTECH USA, INC.	 	 	 
	 	 	 	 	 
	By:	                   	 	By:	              
	Name:
    	 	 	Name:
    	 
	Title:
    	 	 	Title:	 

 

 

 

 

 

**Signature
Page to Amendment No. 1 to Convertible Promissory Note

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]